Page last updated: 2024-11-06

2-bromo-1,4-naphthoquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-bromo-1,4-naphthoquinone is a synthetic compound that has been studied for its potential biological activity. It is a derivative of 1,4-naphthoquinone, a naturally occurring compound found in plants. 2-bromo-1,4-naphthoquinone has been shown to have antimicrobial and anticancer properties. The compound is synthesized by bromination of 1,4-naphthoquinone. Research on 2-bromo-1,4-naphthoquinone focuses on understanding its mechanism of action and exploring its potential therapeutic applications.'

2-bromo-1,4-naphthoquinone: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID74944
CHEMBL ID349148
SCHEMBL ID312893
MeSH IDM0521861

Synonyms (43)

Synonym
1,4-naphthalenedione, 2-bromo-
2-bromonaphthalene-1,4-dione
c10h5bro2
AG-690/11959356
2-bromonaphthoquinone
nsc-401097
3-bromo-1,4-naphthoquinone
nsc401097
2-bromo-1,4-naphthoquinone
2065-37-4
kjohpbjyggfybj-uhfffaoysa-
inchi=1/c10h5bro2/c11-8-5-9(12)6-3-1-2-4-7(6)10(8)13/h1-5h
2-bromo-1,4-naphthoquinone, 98%
CHEMBL349148
2-bromo-[1,4]naphthoquinone
AKOS005207244
nsc 401097
1,4-naphthoquinone, 2-bromo-
FT-0688579
AM84715
2-bromo-1 4-naphthoquinone 98
SCHEMBL312893
KJOHPBJYGGFYBJ-UHFFFAOYSA-N
2-bromo-1,4-napthoquinone
bromonaphthoquinone
1,4-naphthalenedione, 2-bromo- (9ci)
DTXSID90174688
2-bromo-naphthalene-1,4-dione
J-013492
2-bromo-1,4-dihydronaphthalene-1,4-dione
mfcd00629301
AS-50048
2-brom-1,4-naphthochinon
A879516
O10702
CAA06537
CS-0144668
EN300-8161445
2-bromo-p-naphthoquinone
T3SMU54CXM
2-bromo-1,4-naphthalenedione
3-bromonaphthoquinone
SY110606
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
endopeptidase activityCathepsin BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
lysosomeCathepsin BBos taurus (cattle)
apical plasma membraneCathepsin BBos taurus (cattle)
melanosomeCathepsin BBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (14)

Assay IDTitleYearJournalArticle
AID703489Inhibition of human rhinovirus 14 recombinant N-terminal GST-tagged protease 3c expressed in Escherichia coli DH5alpha using LEVLFQGPSK(Fluoro)G as substrate after 1 hr by discontinuous heterogeneous fluorometric assay2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
A simple solid phase, peptide-based fluorescent assay for the efficient and universal screening of HRV 3C protease inhibitors.
AID1416035Inhibition of recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay relative to contr2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1416037Inhibition of recombinant human carbonic anhydrase 2 expressed in Escherichia coli BL21 (DE3) assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration assay relative to control2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID19426HPLC capacity factor (logK)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID660266Trypanocidal activity against bloodstream form of Trypanosoma cruzi Y isolated from albino mouse blood after 24 hrs by neubauer chamber analysis2012European journal of medicinal chemistry, Jun, Volume: 52On the search for potential anti-Trypanosoma cruzi drugs: synthesis and biological evaluation of 2-hydroxy-3-methylamino and 1,2,3-triazolic naphthoquinoidal compounds obtained by click chemistry reactions.
AID19838Partition coefficient (logP)1996Journal of medicinal chemistry, Feb-02, Volume: 39, Issue:3
In vivo activity and hydrophobicity of cytostatic aziridinyl quinones.
AID308238Inhibition of pig pancreatic elastase2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors.
AID1416036Inhibition of recombinant Mycobacterium tuberculosis N-terminal Hi-tagged Rv3588c expressed in Escherichia coli BL21-Al cells assessed as enzyme residual activity at 25 uM measured for 10 secs by m-cresol purple staining based stopped-flow CO2 hydration a2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID1754246Inhibition of recombinant Trypanosoma cruzi cruzain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
AID1507435Antitrypanosomal activity against bloodstream forms of Trypanosoma cruzi Y isolated from parasite infected Albino Swiss mouse assessed as induction of parasite lysis incubated for 24 hrs by Neubauer chamber based cell counting method2017European journal of medicinal chemistry, Aug-18, Volume: 136Rhodium-catalyzed C-H bond activation for the synthesis of quinonoid compounds: Significant Anti-Trypanosoma cruzi activities and electrochemical studies of functionalized quinones.
AID90977Percentage growth inhibition of Toxoplasma gondii at concentration of 2 ug/mL using an human myelomonocytic cell line THP-12000Bioorganic & medicinal chemistry letters, May-01, Volume: 10, Issue:9
Quinonic derivatives active against a virulent strain of Toxoplasma gondii. Synthesis of 2-methylfuro[2,3-g]- and [3,2-g]isoquinolinetriones.
AID1416034Binding affinity to recombinant Mycobacterium tuberculosis Rv1284 expressed in Escherichia coli BL21-Al cells assessed as change in melting temperature by SYPRO Orange dye based differential scanning fluorimetric method2017MedChemComm, Jun-01, Volume: 8, Issue:6
Dichloro-naphthoquinone as a non-classical inhibitor of the mycobacterial carbonic anhydrase Rv3588c.
AID308234Inhibition of papain2007Bioorganic & medicinal chemistry, Aug-01, Volume: 15, Issue:15
The 1,4-naphthoquinone scaffold in the design of cysteine protease inhibitors.
AID1754248Inhibition of recombinant Trypanosoma brucei rhodesain at 100 uM using Z-FR-AMC as substrate preincubated for 10 mins followed by substrate addition measured for 5 mins by fluorimetric analysis relative to control
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.73

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.73 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.92 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.73)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]